All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Bookmark this article
The AML Hub was pleased to speak with Uwe Platzbecker, University of Leipzig Medical Center, Leipzig, DE. We asked, In the current acute myeloid leukemia (AML) treatment landscape, when is anti-infection and anti-fungal prophylaxis recommended?
In the current AML treatment landscape, when is anti-infection and anti-fungal prophylaxis recommended?
Platzbecker begins by explaining that while both the symptoms of AML and treatment for AML can cause neutropenia, increasing patients’ susceptibility to bacterial or fungal infections, antibiotic prophylaxis is not normally recommended at this stage. He highlights the lack of randomized clinical trials investigating the use of general antibiotic prophylaxis in these patients, and differentiates this from neutropenic fever when antibiotic therapy is essential.
Platzbecker goes on to discuss antifungal prophylaxis, including a randomized clinical trial that has shown benefit of posaconazole compared with current standard of care, and how posaconazole prophylaxis is therefore recommended during intensive chemotherapy in patients with neutropenia. However, he highlights the cytochrome interactions necessitating dose reductions of venetoclax or ivosidenib when antifungal agents are given, and advises caution when using these combinations.
“How I treat” case studies incorporating updated classification systems
Here, we summarize key points from a “How I treat” article by Chaer et al., published in Blood, discussing the treatment of patients with AML under the new ELN, ICC, and WHO...
Updated guidelines on antifungal prophylaxis in adult patients with acute myeloid leukemia
A summary of the expert consensus recommendations from the European Hematology Association for antifungal use in adult patients treated with novel targeted...
Subscribe to get the best content related to AML delivered to your inbox